Chronic Illness | Novartis

Media Release
May 31, 2024
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
Media Release
Mar 04, 2024
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Media Release
Nov 09, 2023
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
Media Release
Oct 31, 2023
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
Media Release
Aug 09, 2023
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
Interior Page
Immunology
Story
Apr 07, 2022
Tackling the health toll of climate change
Media Release
Nov 08, 2021
Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021
Media Release
Oct 29, 2020
Novartis presents latest Phase III data reinforcing Cosentyx® as a first-line systemic treatment in pediatric psoriasis
Media Release
Jun 01, 2021
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Media Release
Jun 02, 2021
Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021
Media Release
Jan 06, 2020
Novartis completes tender offer for all outstanding shares of The Medicines Company